Calquense for CLL – pro
NCCN recommend acalabrutinib with a category 2A
recommendation for:
• relapsed/refractory CLL without del(17p)/TP53 mutation in frail
patients with significant comorbidity or in patients ≥65 y and
younger patients with significant comorbidities
• relapsed/refractory CLL without del(17p)/TP53 mutation in
patients <65 y without significant comorbidities
• relapsed/refractory CLL with del(17p)/TP53 mutation
November 21, 2019 – The FDA announced the approval of AstraZeneca’s Calquence (acalabrutinib), for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Download PDF
Byrd J, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in
Relapsed Chronic Lymphocytic Leukemia. N Engl J Med
2016;374:323-332.
Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in
patients with relapsed/refractory chronic lymphocytic leukemia:
Updated results from the phase 1/2 ACE-CL-001 Study [abstract].
Blood 2017;130: Abstract 498.
NCCN, CLL/SLL 2021